Targeting YAP with statins to prevent antibody-mediated transplant rejection
用他汀类药物靶向 YAP 预防抗体介导的移植排斥
基本信息
- 批准号:10320048
- 负责人:
- 金额:$ 24.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-18 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:ActinsAllograftingAntibodiesBindingBlood VesselsCell ProliferationCell TransplantationCellsCharacteristicsCholesterolChronicClinicalDevelopmentElementsEndothelial CellsExhibitsFDA approvedFamilyGenetic TranscriptionGraft RejectionGrowthGuidelinesHeart TransplantationHumanInjuryLesionLigationLipidsMediatingModelingMolecularOrgan TransplantationPI3K/AKTPTK2 genePathogenesisPathway interactionsPatientsPerivascular FibrosisPharmaceutical PreparationsPhosphorylationPlayPopulationPreventionProcessProteinsRegulationRiskRoleSignal PathwaySignal TransductionSolidSurfaceTranscription CoactivatorTransplantationVascular Diseasesantibody-mediated rejectionbasecell growthcell motilitycrosslinkdonor-specific antibodyepidemiology studyheart allograftin vivomigrationmouse modelnovelorgan transplant recipientparalogous genepreventprogramsprotein functionresponserhosrc-Family Kinasestargeted treatmenttherapeutic targettherapeutically effectivetranscription factor
项目摘要
ABSTRACT
Solid organ transplant recipients exhibiting HLA donor specific antibodies (DSA) are at risk for graft loss due
to chronic antibody-mediated rejection (cAMR) and develop a progressive vascular disease known as
transplant vasculopathy (TV). Although cAMR and TV are highly significant clinical problems across different
solid organ transplants the mechanisms by which DSAs directed against HLA I and HLA II contribute to cAMR
and TV are not yet understood. Previously, we demonstrated that DSA-induced ligation of HLA molecules
expressed in the surface of ECs induces signaling pathways, including FAK/Src, PI3K/AKT, mTORC1/2 and
ERK that regulate survival, proliferation and migration, all of which are highly relevant to TV. However, the key
transcriptional programs stimulated by these signals remain to be identified. Based on new preliminary results,
we posit that the transcriptional co-activator Yes-Associated Protein (YAP) and its paralog WW-domain-
containing Transcriptional co-Activator with PDZ-binding motif (TAZ), two central effectors of the Hippo
pathway, are downstream points of convergence in the signaling cascade initiated by DSAs. Although inhibition
of the activity of transcription factors or their co-activators is a challenging strategy, recent evidence suggests
a new avenue to target YAP/TAZ activity via lipid-lowering drugs of the statin family. Importantly,
epidemiological studies strongly indicate that statins exert a beneficial effect in clinical transplant populations.
However, the molecular mechanism remain poorly understood. This gap in understanding hinders effective
therapeutic targeting of DSA effector functions to prevent cAMR and TV. The central hypothesis of this
proposal is that YAP and its paralog TAZ play a crucial role in promoting the proliferation and migration of ECs
in response to DSAs. A second hypothesis is that the FDA-approved drugs of the statin family inhibit YAP
function in these cells. Thus, drugs of the statin family can be an important element in preventing cAMR via
blocking growth-promoting YAP/TAZ signaling in ECs. We will explore these hypotheses by pursuing three
Specific Aims: 1) Determine the regulation and function of YAP in human ECs stimulated with antibodies
directed against HLA I or HLA II: role of Src kinases. 2) Define the mechanism(s) by which statins inhibit YAP
function, proliferation and migration of ECs stimulated with antibodies directed against HLA I or HLA II. 3)
Characterize the impact of statins on YAP and cAMR in vivo using a novel model of heart graft allograft that
develop TV. We anticipate that the YAP/TAZ axis plays a critical role in antibody-mediated EC proliferation
and that statins inhibit EC proliferation and TV via YAP/TAZ inhibition. If the experimental results substantiate
our hypotheses, YAP/TAZ will emerge as novel targets for developing new and potent drugs for preventing
chronic allograft injury induced by DSAs.
摘要
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance.
- DOI:10.3390/cancers13205126
- 发表时间:2021-10-13
- 期刊:
- 影响因子:5.2
- 作者:Rozengurt E;Eibl G
- 通讯作者:Eibl G
Obesity and Pancreatic Cancer: Insight into Mechanisms.
- DOI:10.3390/cancers13205067
- 发表时间:2021-10-10
- 期刊:
- 影响因子:5.2
- 作者:Eibl G;Rozengurt E
- 通讯作者:Rozengurt E
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELAINE F REED其他文献
ELAINE F REED的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELAINE F REED', 18)}}的其他基金
Human Immunomics & Trained Immunity in Persistent Candidemia
人类免疫组学
- 批准号:
10551710 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
The role of HLA and its coreceptors in endothelial cell activation and leukocyte recruitment in antibody-mediated transplant rejection
HLA 及其辅助受体在抗体介导的移植排斥中内皮细胞激活和白细胞募集中的作用
- 批准号:
10231220 - 财政年份:2018
- 资助金额:
$ 24.89万 - 项目类别:
The role of HLA and its coreceptors in endothelial cell activation and leukocyte recruitment in antibody-mediated transplant rejection
HLA 及其辅助受体在抗体介导的移植排斥中内皮细胞激活和白细胞募集中的作用
- 批准号:
10462514 - 财政年份:2018
- 资助金额:
$ 24.89万 - 项目类别:
Mapping Immune Responses to CMV in Renal Transplant Recipients - Transplant Supplement
绘制肾移植受者对 CMV 的免疫反应 - Transplant Supplement
- 批准号:
10225673 - 财政年份:2017
- 资助金额:
$ 24.89万 - 项目类别:
Mapping Immune Responses to CMV in Renal Transplant Recipients
绘制肾移植受者对 CMV 的免疫反应
- 批准号:
10000838 - 财政年份:2017
- 资助金额:
$ 24.89万 - 项目类别:
Ischemia-Reperfusion Injury in Human Liver Transplantation: Reciprocal Regulation of Innate/Adaptive Immune Responses
人肝移植中的缺血再灌注损伤:先天/适应性免疫反应的相互调节
- 批准号:
9975701 - 财政年份:2017
- 资助金额:
$ 24.89万 - 项目类别:
Mapping Immune Responses to CMV in Renal Transplant Recipients
绘制肾移植受者对 CMV 的免疫反应
- 批准号:
10225355 - 财政年份:2017
- 资助金额:
$ 24.89万 - 项目类别:
相似海外基金
Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
- 批准号:
26462277 - 财政年份:2014
- 资助金额:
$ 24.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
- 批准号:
8344380 - 财政年份:2012
- 资助金额:
$ 24.89万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7878675 - 财政年份:2009
- 资助金额:
$ 24.89万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7677758 - 财政年份:2009
- 资助金额:
$ 24.89万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7466112 - 财政年份:2008
- 资助金额:
$ 24.89万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8010394 - 财政年份:2008
- 资助金额:
$ 24.89万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8208131 - 财政年份:2008
- 资助金额:
$ 24.89万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7575273 - 财政年份:2008
- 资助金额:
$ 24.89万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7765518 - 财政年份:2008
- 资助金额:
$ 24.89万 - 项目类别: